Cytomegalovirus (CMV) is a prevalent human pathogen. The virus cannot be eliminated from the body, but is kept in check by CMV-specific T cells. Patients with an insufficient T-cell response, such as transplant recipients, are at high risk of developing CMV disease. However, 30 the CMV-specific T-cell repertoire is complex, and is not yet clear which T cells protect best against virus reactivation and disease. Here we present a highly resolved characterization of CMV-specific CD8+ T cells based on enrichment by specific peptide stimulation and mRNA sequencing of their T-cell receptor β chains (TCRβ). Our analysis included recently identified T-cell epitopes restricted through HLA-C, whose presentation is resistant to viral 35 immunomodulation, and well-studied HLA-B-restricted epitopes. In 8 healthy virus carriers, we identified a total of 1052 CMV-specific TCRβ chains. HLA-C-restricted, CMV-specific TCRβ clonotypes the ex vivo T-cell response, and contributed the highest-frequency clonotype of the entire repertoire in 2 of 8 donors. We analyzed sharing and similarity of CMV-specific TCRβ sequences and identified 63 public or related sequences belonging to 17 public TCRβ 40 families. In our cohort and in an independent cohort of 352 donors, the cumulative frequency of these public TCRβ family members was a highly discriminatory indicator of carrying both CMV infection and the relevant HLA type. Based on these findings, we propose CMV-specific TCRβ signatures as a biomarker for an antiviral T-cell response to identify patients in need of treatment and to guide future development of immunotherapy. 45 3
Introduction

50
Like other members of the herpesvirus family, human cytomegalovirus (CMV) infects its carriers for life, and prevention of overt disease requires a protective repertoire of virus-specific T cells (1, 2) . Persons who lack such a T-cell repertoire, such as patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT), are at risk of reactivating latent CMV infection, and CMV disease remains a threat to their survival and well-being (3) . Conventional 55 antiviral chemotherapy has significant adverse effects, is not universally effective, may delay viral reactivation rather than prevent it, and is subverted by viral resistance (3, 4) .
Re-establishment of a functional and durable antiviral T-cell repertoire is expected to enable patients to control CMV infection for their lifetime. Transfer of CMV-specific T cells from immunocompetent donors to patients after allo-HSCT has yielded encouraging results over the 60 last three decades (5, 6) . However, most of these trials were of small to medium scale and without randomized controls. Preliminary reports on two recent large randomized controlled trials suggest efficacy (5) , but complete analysis is not yet available.
Therefore, present capability to clinically exploit the CMV-specific T-cell repertoire is limited.
Although the CMV-specific T-cell response has been studied in great detail (7) , fundamental 65 questions remain unanswered. No consensus has been reached on which viral antigens and epitopes induce T-cell responses that directly protect against infection, and which T-cell specificities are merely correlated with the presence of other, more effective specificities (7) .
The challenge of understanding the CMV-specific T-cell repertoire is formidable, since CMV expresses more than 200 viral proteins and has evolved multiple mechanisms to interfere with 70 T-cell recognition by modulating cytokine and chemokine responses, antigen processing, intracellular peptide translocation, stability of HLA molecules, and more (8, 9) . Moreover, human CMV shows sequence variation, and some specific T cells may recognize only certain strain-specific epitope variants (10) .
A particularly strong CD8+ T-cell response is directed to two viral antigens with contrasting 75 functional roles and kinetics of expression: the transcription factor IE-1 and the structural protein pp65 (11, 12) . Earlier data indicated that pp65-specific CD8+ T cells were the most effective in attacking infected cells in vitro (13) , whereas IE-1-specific T cells were more strongly associated with reduced viral reactivation in patients after transplantation (14, 15) and protective in the murine CMV model (16) . Our recent findings suggested that viral 80 immunoevasion is not predominantly guided by the identity of the antigen, but by the identity of the epitope and the HLA class I molecule that presents it (17, 18). For example, we identified an HLA-C-restricted CD8+ T-cell epitope from IE-1 whose presentation is highly resistant to viral immunomodulation. T cells specific for this epitope are of high incidence and frequency in healthy donors (17, 18) . These properties are shared (19) by a second CD8+ T-cell epitope 85 restricted through the same HLA (20) ; this epitope is derived from the rarely studied UL29/28-encoded CMV protein. It is unknown whether there is a causal relationship between escape of certain epitopes from viral immunomodulation and high incidence of epitope-specific T cells, and whether T cells against such epitopes are associated with protection from reactivation. To address such questions, the CMV-specific T-cell response needs to be analyzed and understood 90 in much more detail, using methods that are of sufficient resolution to adequately cover the complexity of the repertoire. High-resolution sequencing of the T-cell receptor (TCR) is such a method.
Most human T cells express a heterodimeric αβ TCR that specifically recognizes the antigenic target, a complex of an HLA molecule and a peptide. Both chains, α and β, have highly variable 95 sequences. The specificity of each αβ T cell is ensured by its expression of only one TCRβ chain and one or, occasionally, two TCRα chains (21) . Variability of TCR sequence is produced by recombination in the thymus. In the case of the human TCRβ chain, a V(D)J reading frame is produced by imprecisely joining one of 46 functional V genes, one of two short D genes, and one of 13 J genes, mostly with insertion of template-independent nucleotides between the genes 100 (22, 23) . The sequence around these junctions encodes the CDR3, a loop that reaches out to the peptide embedded in the HLA molecule (24) . The number of different TCRβ chains in the Tcell repertoire of a human being was estimated to be in the range of millions (25) (26) (27) or even hundreds of millions (28) ; this is only a small fraction of the diversity that is theoretically possible (22, 27) . CMV-specific TCR repertoires have been studied in detail before (29) (30) (31) , 105 but most studies were limited to pp65 and HLA-C-restricted T cells were not included. The advent of massively parallel sequencing of TCR-encoding DNA or mRNA (26, 32) has now made it possible to identify the specificity-defining element of millions of T cells in a sample, and pioneering studies have applied this technique to the analysis of CMV-specific T cells (33-
36). 110
Here we use high-resolution TCRβ sequencing to investigate the repertoire of CMV-specific CD8+ T cells, focusing on previously unstudied HLA-C-restricted T cells that promise to be of high clinical interest. Specific T cells were selectively enriched by peptide-driven in vitro expansion; this method is transferable to settings when samples are small or HLA/peptide multimers are not available. We found that T cells specific for HLA-C-restricted CMV epitopes 115 showed exceptional clonal dominance within the overall TCRβ repertoire. Moreover, we identified a set of public and related CMV-specific TCRβ sequences that reliably distinguished persons with or without CMV-specific T-cell immunity, immediately suggesting future application of this method in clinical immunomonitoring.
120
Materials and Methods
Blood donors
Human T cells were derived from anonymous peripheral blood buffy coats purchased from Institut für Transfusionsmedizin, Ulm, Germany. The institutional review board 125 (Ethikkommission bei der LMU München, Project No. 17-455, 16.10.2017 ) has approved our use of anonymous human material. We did not seek or obtain consent since all material and data were obtained anonymously. Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation and cryopreserved until use. Donors were HLA-typed at 4-digit resolution (MVZ, Martinsried, Germany). All donors were positive for HLA-B*07:02 and 130 HLA-C*07:02. CMV status (Supplementary Table 1 ) was determined by anti-CMV IgG ELISA (Siemens).
Peptide stimulation assay
The four CMV-derived peptides CRVLCCYVL (CRV, HLA-C*07:02, IE-1), FRCPRRFCF 135 (FRC, HLA-C*07:02, UL28), RPHERNGFTVL (RPH, HLA-B*07:02, pp65), and TPRVTGGGAM (TPR, HLA-B*07:02, pp65) (Supplementary Table 1) were separately used to stimulate and selectively expand virus-specific T cells from CMV-positive donors P01-P08.
Cell culture medium was RPMI 1640 (Invitrogen) supplemented with 8% or 10% FCS (BioSell or Invitrogen). Per culture, 25 million PBMCs were suspended in 2 mL cell culture medium 140 containing 5 µg/ml of peptide (JPT, Berlin; ≥70% purity), incubated at 37°C for 1 hour, and washed three times with PBS (PAN Biotech) to remove excess peptide. PBMCs were resuspended in 12.5 ml cell culture medium supplemented with 50 U/ml IL-2 (Proleukin; Novartis) and distributed at 2.5 ml per well to a 12-well plate. The plate was incubated at 37°C and 5% CO2. After 6±1 days, the cells of each well were resuspended, distributed to two wells, 145 and 1 ml of fresh culture medium supplemented with IL-2 was added to each well. Cells were harvested at day 10 of culture.
T-cell stimulation with autologous mini-LCLs
PBMCs from three healthy donors (P01-P03) were infected with empty mini-Epstein-Barr 150 viruses encoding pp65, IE-1, or no CMV protein (37) . The resulting transformed B cell lines Total RNA was extracted from PBMCs, T-cell cultures, or CD8-enriched T cells using the 165
Qiagen RNeasy Kit (Qiagen). 1 µg RNA per sample was reversely transcribed to cDNA with the QuantiTect Reverse Transcription Kit (Qiagen) using a primer designed to target both the Cb1 and Cb2 regions of the TCR RNA (5'-GCACC TCCTT CCCAT TCAC-3'). cDNA was amplified in two subsequent PCRs using Pfu DNA polymerase on a thermocycler (Biometra T Gradient). Both PCRs were initiated at 95°C for 2 min; cycles consisted of incubation at 95°C 170 (30 sec), 65°C (30 sec), and 72°C (60 sec); final elongation was at 72°C (10 min). The first reaction was a multiplex PCR with 42 distinct forward primers that bind to the Vb region and cover all possible human TCR Vb segments, and a reverse primer that anneals to the Cb1 and Cb2 regions; the Cβ primer was optimized for this protocol, Vβ binding sites were mostly taken from established protocols (26) . Forward (Vβ) and reverse (Cβ) primers carried sequences 175 complementary to the Illumina Read 2 and Read 1 priming sequence, respectively. To enhance the nucleotide diversity of TCRβ reads, facilitate cluster recognition and avoid artefacts, three different forms of the reverse primer were used, with 0, 1 or 2 degenerated nucleotides (N) inserted between the Cb-binding sequence and the Illumina Read 1 sequence. All primers were used in equimolar amounts (a total of 10 µM; for primer sequences see Supplementary Table 1) . 180
The first PCR consisted of only 10 amplification cycles to minimize PCR amplification bias.
The second PCR was performed with index primers (NEBNext Multiplex Oligos for Illumina; New England BioLabs), to attach barcodes and the i5 and i7 adapters for cluster generation on the Illumina flow cell ( Figure 1B ). After each PCR step, the PCR product was purified using Agencourt AMPure XP magnetic beads (Beckman Coulter). Length and quantity of PCR 185 products for sequencing was determined using the Agilent DNA 1000 Kit and the Bioanalyzer 2100 (Agilent).
High-throughput sequencing and data analysis
The barcoded samples were combined to a final concentration of 10 nM DNA and sequenced 190 with the Illumina HiSeq1500 system in paired-end rapid run mode. The libraries were bidirectionally sequenced with read lengths between 120-175 bp in each direction.
Raw data were demultiplexed and quality-filtered using web-based tools on the Galaxy platform. Next, all reads were aligned to the matching Vb, Jb and Cb genes, TCRb clonotypes were built from identical sequences, and similar clonotypes were clustered with the MiXCR 195 software (38) . TCR clonotype data were further processed using custom scripts in R, in order to compare samples and characterize specificity and sharing of TCRb sequences. Graphs were made with R, GraphPad Prism, or Microsoft Excel. P values were calculated with two-sided Mann-Whitney U tests in GraphPad Prism, version 7. U, respectively. The read count at a local minimum of each of these two distributions was identified, and the mean of these two read counts served as the cut-off value. If any of these two density distributions did not have a local minimum, the cut-off was positioned at its global maximum times 100, i.e. at 100 reads in sample S or higher.
Using these criteria, specific TCRβ clonotypes were identified for 8 CMV-positive donors 220 (P01-P08) and four epitopes (CRV, FRC, RPH, and TPR), resulting in identification of 1052 CMV peptide-specific TCRb sequences which were unique at the amino acid level (all specific sequences are listed in Supplementary Table 2 ). Identification of antigen-specific TCRb sequences from mini-LCL stimulations was achieved in a similar manner by comparing the frequencies of each clonotype in the CMV antigen-stimulated sample to their ex vivo 225 frequencies and the frequencies in the samples obtained by stimulation with an empty-vector mini-LCL control. Only TCRb sequences that were enriched compared to both control samples were considered specific for epitopes from that CMV antigen.
Identification of public and related TCRb sequences 230
Public CMV epitope-specific TCRb sequences and TCRb families were identified based on 1052 specific TCRb sequences from donors P01-P08. In a first step, TCRb sequences were categorized as public if they were CMV-specific in at least two donors with identical Vb and Jb gene segments, CDR3 amino acid sequence, and epitope specificity. In a second step, this set of sequences was extended by such TCRb sequences that were present in only one donor, 235 but highly similar to public TCRb sequences. Sequences were considered highly similar if (a) they used the same Vb gene segments, (b) had the same CDR3 length, and (c) differed in maximally two amino acids in the CDR3.
Results
240
A method for high-resolution TCRβ repertoire analysis by peptide stimulation
We devised a method to analyze human epitope-specific TCRβ repertoires at high resolution. TCRβ cDNA libraries for Illumina sequencing were prepared from T-cell samples in a 2-step 255
RT-PCR ( Figure 1B) . The 2-step PCR procedure was designed to limit potential amplification bias due to multiplex priming and to increase fidelity by enabling bidirectional sequencing of the CDR3. After Illumina sequencing, TCRβ clonotypes were built using the software MiXCR (38) . A median of 5.0 × 10 6 productive TCRb sequence reads were obtained per sample (Supplementary Table 2 ). When we plotted TCRβ clonotype frequencies before and after 260 stimulation, well-separated clusters suggestive of peptide-reactive expanded TCRb clonotypes became apparent in CMV-positive, but not in CMV-negative donors (Figure 2) . For a more precise definition, we evaluated TCRb sequences to be epitope-specific if they appeared in the cluster of enriched clonotypes after cultivation with a specific peptide, but not after cultivation with a control peptide of different HLA restriction (three-sample comparison, enrichment cut-265 off). In addition, a frequency cut-off was applied to minimize statistical noise from lowfrequency clonotypes (Supplementary Figure 1) ; this cut-off was calculated from the samplespecific clonotype frequency distribution.
We identified a total of 1052 unique TCRb amino acid sequences in 8 CMV-positive donors (P01-P08) that met the specificity criteria for exactly one epitope (listed in Supplementary 270 Table 2 ). Of these, 435 were specific for CRV, 266 for FRC, 191 for RPH, and 160 for TPR.
Nineteen TCRβ sequences passed the criteria for two epitopes, no TCRβ for more than two epitopes. Thus, we observed minor overlap between TCRβ sequences assigned to different specificities.
275
Peptide stimulation expands T-cell clonotypes that recognize processed antigen
There is a concern that synthetic peptide may not exclusively stimulate T cells that will be able to recognize the naturally processed epitope (43) . Therefore, we tested whether our peptide- Table 2 ) were compared with those obtained through peptide 285 stimulation. In the mini-LCL condition, TCRb sequences were considered CMV-specific if they were enriched by stimulation with mini-LCLs that expressed the CMV antigen of interest, but not by stimulation with control mini-LCLs that lacked the CMV antigen. We found that the majority of TCRb clonotypes that were expanded by one of the peptides CRV, RPH, or TPR also recognized the corresponding CMV antigen processed by mini-LCLs (Figure 3 ). These 290 results confirm that our simple peptide stimulation assay is a generally valid approach for the identification of CMV-specific TCRb clonotypes of both high and low frequency.
CMV-specific TCRb clonotypes are abundant in the T-cell repertoire of virus carriers
We investigated the contribution of CMV epitope-specific T-cell receptors to the overall TCRb 295 repertoire in peripheral blood of 8 CMV-positive (P01-P08) and 8 CMV-negative (N01-N08) donors. Among the top 100 most frequent ex vivo TCRb clonotypes of any CMV-positive donor ( Figure 4A ), 2 to 10 were specific for one of the CMV epitopes CRV, FRC, or TPR. In 7 of 8 CMV-positive donors, CMV-specific clonotypes were among the 5 most frequent clonotypes, and in 2 of 8 donors, they supplied the top-frequency clonotype of the entire repertoire. Among 300 a donor's CMV-specific clonotypes, the most frequent one was specific for CRV in 6 and specific for FRC in 2 of 8 donors. In CMV-negative donors, none of the top 100
TCRβ clonotypes were specifically enriched by CMV peptide stimulation, and thus none of them was categorized as CMV-specific. When looking at the cumulative read frequencies, CRV-or FRC-specific clonotypes dominated the response in CMV carriers ( Figure 4B) . These 305 results demonstrate that CMV-specific T cells distinctly shape the T-cell repertoire of virus carriers, with a prominent role for HLA-C-restricted clonotypes.
Patterns of Vb and Jb gene segment usage in CMV epitope-specific TCRs
We analyzed TCRb clonotypes sharing their epitope specificity for shared structural features. 310
First, we evaluated overall use of Vb and Jb gene segments ( Figure 5 ) in CMV-specific TCRb clonotypes. For each epitope, particular Vb and Jb genes were overrepresented, such as Vb-6-1/-5/-6, Vb25-1 and Vb28, and Jb1-1, Jb2-1 or Jb2-7 for epitope CRV. However, no Vβ-Jβ combination dominated the response to any of the four epitopes. It follows that gene segment use alone is not sufficiently informative as a marker of CMV-specific CD8+ T-cell immunity 315 to the epitopes studied here.
Public CMV-specific TCRb sequences and TCRb families
Next, we searched for the presence of identical TCRb amino acid sequences with the same CMV epitope specificity in different donors, known as shared or public TCRs. We found 26 320
TCRb sequences that were specific in at least 2 out of 8 CMV-positive donors ( Table 1) . Several of these public sequences with the same epitope specificity were closely related in sequence, since they used the same Vb gene, had the same CDR3 length, and differed in a maximum of 2 amino acids within the CDR3. Hence, we looked for additional TCRb sequences that appeared in only one of the 8 donors, but were closely related to one of the 26 public TCRb 325 sequences according to the criteria stated above; we identified 37 such TCRb sequences. The resulting set of 63 public or related CMV-specific TCRb sequences was composed of 17 similarity groups, which we refer to as public TCRβ families. Of the 63 sequences, 21 were HLA-B-restricted (epitopes TPR and RPH), and 10 of them had been previously described (29, 42, 46, 47) . In contrast, the epitope specificity and HLA restriction of none of the 42 HLA-C-330 restricted TCRb sequences (epitopes CRV or FRC) had been previously shown, although 5 of these sequences were found to be enriched in CMV-positive donors compared to CMVnegative donors (48). Table 3 ). Mean cumulative frequency in donors P09-P16 and donors P01-P08 was similar, which showed that there was no 355 bias in favor of the P01-P08 cohort of donors in whom the sequences were originally identified.
335
To further validate the set of public TCRb families, we tested it on a larger cohort of donors whose ex vivo TCRβ repertoires were recently published (48) and whose CMV status and partial HLA type (low resolution HLA-A and -B, no HLA-C) was available. Since presence of HLA-B7 is a strong indicator of the presence of the haplotype HLA-B*07:02∼C*07:02 in 360 persons of European descent, whereas persons of Asian descent often express HLA-C*07:02 without HLA-B*07:02 (41), we limited our analysis to the 352 donors categorized as "White, not Hispanic or Latino". Of these donors, 94 were HLA-B7-positive, and 258 were HLA-B7-negative. As shown in Figure 6C , CMV-specific public TCRβ families were strongly enriched in HLA-B7-positive, CMV-positive donors, but not in HLA-B7-positive, CMV-negative 365 donors (P < 1 × 10 -15 ). In HLA-B7-negative donors, no enrichment was observed irrespective of CMV status. In a separate analysis of each epitope in this cohort, CRV was the strongest discriminator (P = 7.5 × 10 -13 ; Figure 6B , right).
A chosen cut-off value of 10 -4 for the total proportion of reads of our set of 63 public or related TCRβ sequences lead to perfect discrimination between CMV-positive and CMV-negative 370 donors within our cohort, and very good identification of CMV-positive donors within the HLA-B7-positive published cohort (F1 score = 0.93; 100% specificity, 88% sensitivity). Taken together, our results show that the CMV-specific TCRb signature, as identified through our approach, is highly indicative of CMV-specific T-cell immunity associated with the CMV status in healthy donors. 375
Discussion
Here we analyzed the composition and sharing of TCRβ repertoires against four epitopes that 380 are major targets of the CMV-specific CD8+ T-cell response. Specific TCRs against two of these epitopes, restricted through HLA-C, had not been studied before. We identified a set of CMV-specific public TCRβ families that distinguishes CMV-positive from CMV-negative healthy persons in two independent cohorts with high precision.
We show that the CMV epitopes studied here considerably shape the T-cell repertoire of healthy 385 virus carriers. HLA-C*07:02-restricted T cells were particularly prominent; in 6 of 8 donors they provided one of the four most frequent TCRβ clonotypes to the overall T-cell repertoire, and in 2 of these donors the top-frequency TCRβ clonotype. These results expand on the general observation that CMV-specific T cells make up for a large proportion of the CD8+ T-cell repertoire, on average amounting to 5% of the total CD8+ T-cell response based on interferon-390 γ secretion (49) . This proportion is likely to be even larger when all antigen-specific cells are included in measurements, not just those that exert a chosen effector function at the time of analysis (50) . Advanced donor age boosts CMV-specific T-cell frequencies as well (19) , an aspect we could not investigate in our cohort of anonymous donors.
The TCRβ signatures of the CMV epitope-specific T cells studied here were diverse. For a 395 given epitope, the dominant TCRβ sequence was usually a different one in different donors.
Thus, TCRβ repertoires were not dominated across the board by heavily conserved (public) sequences, in contrast to what was observed for some epitopes from influenza (51, 52) or EBV (53). Rather, the TCRβ repertoires studied here were mostly composed of clonotypes that were shared with only a subset of matched donors, or were entirely donor-specific (private). These 400 patterns are reminiscent of those previously found for TCR repertoires of HLA-A-and HLA-Brestricted CMV-specific T cells (29-31, 33, 34, 54, 55) . Nonetheless, our approach identified a series of public TCRβ chains whose cumulative frequency was strongly indicative of CMV carrier status in larger cohorts of healthy donors, even though these public TCRs did not necessarily represent the most abundant epitope-specific T cells in the 8 donors in whom they 405 were originally identified. It seems clear that exclusive TCRβ sequencing underestimates the true diversity of an epitope-specific T-cell response, since the same TCRβ can be paired with different TCRα chains to generate the same or an overlapping human antiviral epitope specificity (53, 56, 57). However, our results show that TCRβ sequencing, even in the absence of TCRα analysis, is already highly informative regarding the CMV-specific T-cell status of 410 donors. This finding may already have been anticipated by a recent large-scale study (48), which showed that signatures of enriched TCRβ sequences distinguished CMV-positive from CMV-negative donors with high precision. Our study extends these findings by demonstrating the predictive power of TCRβ sequences with known CMV epitope specificity. In contrast, the previous study (48) analyzed TCRβ sequences that were CMV-associated, but mostly not 415 known to be CMV-specific, which means that other pathogens with overlapping epidemiology may have contributed to the signal. For future diagnostic or prognostic applications in immunocompromised patients, it will be preferable to focus on analysis of precisely defined antigen-specific TCRβs, since such patients may simultaneously reactivate or acquire multiple, and even related, pathogens. We conclude that TCRβ sequencing provides a highly informative 420 and economic standalone approach to identification of epitope-specific T cells in healthy carriers and patients at risk of viral reactivation and in potential need of antiviral prophylaxis or treatment (1, 58, 59 ).
Conserved TCRβ chains are not necessarily perfectly conserved. It was often observed that human HLA-A-or HLA-B-restricted CD8+ T-cell responses to an epitope contain non-425 identical but highly similar TCRβ chains; these use the same or closely related Vβ and Jβ segments and typically have CDR3 regions that show exchanges in only few amino acid positions. Such relationships are apparent in datasets on multiple epitopes from CMV (29, 31, 42, 55, 60, 61) , EBV (29, 31, 53, (61) (62) (63) (64) , HIV (29), or influenza virus (51, 52) . Similarity between TCRβ chains of the same specificity can also manifest as the presence of conserved 430 short motifs within the CDR3 (29, 52) , often at or near residues 6 and 7; these residues are at its center and generally make strong contributions to binding of MHC/peptide by the TCR and shaping T-cell specificity (65) . Analysis of such TCRβ relationships was recently taken to a more comprehensive level (33, 34) by the design of computational algorithms to cluster T cells of the same specificity according to multiple indicators of sequence similarity. Global sequence 435 similarity of the CDR3 is the single factor that predicts specificity best (34) , and prediction is further improved by adding aspects such as CDR3 length and Vβ gene segment usage.
Accordingly, we observed multiple occurrences of high similarity of CDR3 sequence, length and Vβ usage among our 26 CMV-specific public TCRs. Therefore, we decided to group CMVspecific public and related TCRβs into families based on these criteria. We found that TCRβ 440 families that were defined in this way could precisely distinguish healthy persons with and without established CMV-specific T-cell immunity. Public TCRβ family sequences were as rare in CMV-negative persons who carry the relevant HLA haplotype as in CMV-positive persons who lack the HLA haplotype. This finding shows that such TCRβ family members are unlikely to appear in T cells of irrelevant specificity or HLA restriction, confirms the predictive 445 power of TCRβ sequencing, and suggests that our TCRβ grouping approach can in future studies be extended to a broader variety of epitopes, viruses, or antigenic entities.
Since its initial description (26, 32) , high-throughput sequencing of TCRβ repertoires has become a widely used research method, but it has not yet found wide clinical application. We have now introduced technical improvements that will enhance its robustness and applicability 450 to accelerate advancement to routine clinical use. Dual-indexed, paired-end bidirectional sequencing of the entire CDR3 region is likely to reduce errors in the resulting Illumina sequencing data (66) . Our technique to identify epitope-specific TCRβ repertoires by peptide stimulation and comparison to two controls eliminates the need to physically isolate specific It seems safe to predict that identification and quantification of antigen-specific TCRβ repertoires will increasingly enter clinical practice for purposes of diagnostics and monitoring.
Repositories of annotated antigen-specific TCRs (72), refined computational tools for TCR sequence analysis (38) and TCR sequence datasets (48), generously made available to the 480 public, will be of great use in further developing the method. With growing datasets, an increasing number of epitope-specific TCR sequences against various pathogens will be found to be shared between carriers. Such public TCR sequences will find application in various fields. In clinical research, public TCR sequences may be used as indicators to track virusspecific T-cell responses in patients after transplantation in order to identify epitopes that 485 mobilize a protective T-cell response against pathogens such as CMV (6) . Virus-specific TCR signatures may also be exploited in diagnostics and disease monitoring (36, 73, 74) 
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